More than 6000 high blood pressure specialists from around the world have convened in Madrid for the XVI European Meeting on Hypertension, the annual congress of the European Society of Hypertension, to discuss the latest advances in research, diagnosis, treatment, and prevention. A key change in the meeting this year is a broader focus on all of cardiovascular disease, recognizing that hypertension is the common denominator in cardiovascular disease. Medical education sessions on diabetes, metabolic syndrome, and nephrology are key aspects to broaden the scope of education at this meeting. www.eshonline.org, the official website of the ESH, offers you the opportunity to share the key information “live” from the meeting with a daily coverage including summaries of the breaking news, webcasts of the most important sessions, and video interviews.
XVI European Meeting on Hypertension
Meeting Highlights
- Topical Workshop 8: Anticoagulation in CV Disease
- Topical Workshop 4: A Reappraisal
- TOLERANCE Study: Better blood pressure control and tolerability with lercanidipine
- Teaching Seminar 2: New Data from the ASCOT Trial
- Role of nurses in control of high blood pressure highlighted in ESH Session
- PDE-5 inhibitor sildenafil improves exercise-induced vasodilation
- OPTIMAX: Fixed-dose combination as first-line therapy effective to achieve BP control in primary care
- National Registry: Hypertension not controlled in 76% of patients in primary care
- More patients reach goal blood pressures when GPs receive guideline treatment: VALNORM study
- Hypertension treatment goals not achieved in primary care in Germany
- Global CV risk management a priority, ESH guideline revision considered
- Future hypertension treatment will include targeted, and earlier, treatment
- ESH–ASH Joint Symposium
- ESH–ASH Joint Symposium
- ESH recognizes the Renin Academy
- Endothelial dysfunction a “harbinger” of CVD in hypertensive diabetic patients
- Bring the message home” from ESH: Treat global risk, treat aggressively